Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness.
Insulin sensitivity has been implicated in the variation of fat accumulation in early gestation by as-yet-unknown mechanisms. In the present study, we analyzed the insulin sensitivity of lipolysis and lipogenesis in lumbar adipocytes from rats at 0, 7, 14, and 20 days of gestation. In adipocytes of 7-day pregnant rats, we found a twofold decrease in both beta-agonist (isoproterenol and BRL-37344)-stimulated lipolysis and beta3-adrenoceptor protein but not in lipolysis initiated by forskolin or isobutylmethylxanthine, suggesting a modification of the lipolytic pathway at the receptor level. Whereas adipocytes from 7-day pregnant rats showed a twofold increase in fatty acid synthesis from glucose, those from 20-day pregnant animals displayed a decreased lipogenic activity. Insulin responsiveness of the lipolytic and lipogenic pathways was analyzed by dose-response experiments, giving evidence for the involvement of improved insulin responsiveness in the enhanced lipogenic and reduced lipolytic activities of adipocytes in early pregnancy. In contrast, insulin resistance is responsible for lower antilipolytic and lipogenic actions of insulin in late pregnant animals. In conclusion, the present study shows that enhanced adipose tissue insulin responsiveness during early pregnancy contributes to maternal fat accumulation, whereas decreased insulin responsiveness during late gestation modulates fat breakdown.
Ramos
M P
MP
Facultad de Ciencias Experimentales y de la Salud, Universidad San Pablo-CEU, Ctra. Boadilla del Monte km.5,3, E-28668, Madrid, Spain. pramos@ceu.es
Crespo-Solans
M D
MD
del Campo
S
S
Cacho
J
J
Herrera
E
E
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000273:Adipose Tissue / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D005576:Colforsin / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005865:Gestational Age; D005951:Glucose Tolerance Test; D005990:Glycerol / Q000097:blood; D007328:Insulin / Q000097:blood / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000096:biosynthesis; D008066:Lipolysis / Q000187:drug effects; D008161:Lumbosacral Region; D009929:Organ Size; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D022702:Receptors, Adrenergic, beta-3 / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D001786:Blood Glucose; D004983:Ethanolamines; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D020738:Leptin; D008055:Lipids; D022702:Receptors, Adrenergic, beta-3; D005576:Colforsin; C057368:BRL 37344; D007545:Isoproterenol; D005990:Glycerol; D015056:1-Methyl-3-isobutylxanthine